A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

Summary

The primary purpose is to evaluate the safety and tolerability of ASP6981 in participants with schizophrenia. Also primary purpose is to evaluate the pharmacodynamics of ASP6981 in participants with schizophrenia as measured by cognitive function and neurophysiological biomarkers. The secondary purpose of this study is to evaluate the pharmacokinetics of ASP6981 in participants with schizophrenia.

Timeline

Start

2018-01-22

Primary completion

2018-05-30

Completion

2018-05-30

Drugs

Indications